Editorial comment on: Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02.
Whelan
Peter
P
D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects*; D002318:Cardiovascular Diseases / Q000401:mortality*; D005485:Flutamide / Q000009:adverse effects*; D017273:Goserelin / Q000009:adverse effects*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*
D018931:Antineoplastic Agents, Hormonal; D017273:Goserelin; D005485:Flutamide